Recent guidelines published by the ATA for the treatment of hypothyroidism have created a greater divide between certain schools of thought regarding effective thyroid care. ThyroidChange believes that each patient needs options and protocols for thyroid assessment, and treatment beyond the TSH laboratory test and levothyroxine-only medication. We believe that we can achieve this through cooperation with various organizations that create such guidelines, including the ATA.
ThyroidChange has sent a letter to the ATA Board of Directors in the spirit of collaboration and to minimize the divide between patients and medical professionals who strictly adhere to ATA guidelines. We pose numerous questions for consideration throughout the topics that the ATA plans to discuss including questions surrounding the gold-standard TSH laboratory test and levothyroxine-only therapy. We believe that the patient voice, established research, and physician reports on current best practices in thyroid health care will improve thyroid disease diagnostic and treatment methods. However, it must begin with collaboration.
ThyroidChange believes that an on-going partnership will innovate thyroid health care and will result in the betterment of patient health worldwide. Our volunteers and advisory board are working to build partnerships with medical organizations to address the overwhelming number of people who are either misdiagnosed or present lingering symptoms due to inadequately treated thyroid disease. We are working tirelessly to demonstrate that the patient reactions to the recent guidelines are valid and are backed by scientific evidence.
Thyroid patients and their medical professionals everywhere deserve to achieve the success they cannot find due to the methods detailed in the recent treatment guidelines. The suffering must end. Improvements in thyroid health care will only begin when we join forces. We need change and it begins with collaboration.
To read ThyroidChange's letter to the ATA Board of Directors, please visit click here.